Seqirus

Quick facts

Marketed products

• CSL Influenza Vaccine · Immunology
  This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
• CSL Limited Influenza Vaccine · Immunology
  This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
• CSL Limited Influenza Virus Vaccine · Immunology / Infectious Disease
  This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
• Enzira® vaccine · Immunology / Infectious Disease
  Enzira is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains.

Phase 3 pipeline

• Adjuvanted QIV (aQIV) · Immunology
  Adjuvanted QIV (aQIV) is a quadrivalent influenza vaccine enhanced with an adjuvant to boost immune response against four influenza virus strains.
• aH5N1c · Infectious disease
  aH5N1c is a vaccine that stimulates the body's immune response to the H5N1 subtype of the influenza A virus.
• aQIV
• aQIV or aTIV
• Comparator QIV · Immunology / Infectious Disease
  Comparator QIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus.
• Investigational aQIVc · Immunology / Infectious Disease
  aQIVc is a cell-based quadrivalent influenza vaccine designed to provide broader and more durable immune protection against multiple influenza strains.
• licensed aQIV · Immunology / Infectious Disease
  aQIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four circulating influenza virus strains.
• licensed QIVr · Infectious Disease
  QIVr is a quadrivalent influenza vaccine that stimulates the body's immune system to produce antibodies against four different influenza viruses.
• Non-adjuvanted QIV · Immunology / Infectious Disease
  Non-adjuvanted QIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four influenza virus strains without added adjuvant components.
• Non-influenza Comparator Vaccine · Immunology
  A non-influenza comparator vaccine stimulates the immune system to generate protective antibodies and cellular immunity against a non-influenza pathogen or antigen.
• Novartis Investigational H5N1 vaccine · Immunology / Infectious Disease
  This vaccine stimulates the immune system to produce antibodies and cellular immunity against H5N1 influenza virus.
• Novartis Seasonal Influenza Vaccine · Infectious Diseases
  The vaccine stimulates the immune system to produce antibodies against specific influenza virus strains, thereby preventing infection.
• QIV or TIV · Infectious disease
  QIV or TIV is a vaccine that stimulates the body's immune system to produce antibodies against influenza.
• QIVc · Immunology / Infectious Disease
  QIVc is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus.
• Seqirus QIV · Infectious Disease
  Seqirus QIV is a quadrivalent influenza vaccine that stimulates the body's immune system to produce antibodies against four different influenza viruses.
• Seqirus Quadrivalent Inactivated Influenza Vaccine · Immunology
  This vaccine induces an immune response against multiple influenza strains.

Phase 2 pipeline

• Afluria Influenza Vaccine · Immunology
  Afluria Influenza Vaccine stimulates the body's immune system to produce antibodies against the influenza virus.
• aH5N6c on Day 1
• aH5N6c on Day 22
• aH5N8c on Day 1
• aH5N8c on Day 202
• aH5N8c on Day 22
• aIIV4
• aQII-1
• aQII-10 Investigational
• aQII-11 Investigational
• aQII-3 Investigational
• aQII-6 Investigational
• aQII-9 Investigational
• CSL412 · Infectious Diseases
  CSL412 is a vaccine.
• CSL425 · Immunology / Infectious Disease
  CSL425 is a recombinant human monoclonal antibody that targets and neutralizes respiratory syncytial virus (RSV) to prevent infection.
• Flucelvax Quadrivalent Influenza Vaccine
• Flucelvax Trivalent Influenza Vaccine
• H5N1 antigen combined with MF59 adjuvant
• H5N1 pandemic influenza vaccine
• IIV4c
• Investigational aIIV4c
• RIV4

Phase 1 pipeline

• Adjuvanted, trivalent subunit influenza vaccine
• sa-mRNA vaccine Dose 1
• Trivalent Influenza Vaccine intradermal dose
• Trivalent influenza vaccine-licensed

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Seqirus portfolio CI brief
• Seqirus pipeline updates RSS